...
首页> 外文期刊>Clinical and vaccine immunology: CVI >Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.
【24h】

Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.

机译:脂多糖抗原目标制定一个通用疫苗大肠杆菌O111菌株。

获取原文
获取原文并翻译 | 示例
           

摘要

A promising approach to developing a vaccine against O111 strains of diarrheagenic Escherichia coli that exhibit different mechanisms of virulence is to target either the core or the polysaccharide chain (O antigen) of their lipopolysaccharide (LPS). However, due to structural variations found in both these LPS components, to use them as antigen targets for vaccination, it is necessary to formulate a vaccine able to induce a humoral immune response that can recognize all different variants found in E. coli O111 strains. In this study, it was demonstrated that, despite differences in composition of oligosaccharide repeat units between O111ab and O111ac LPS subtypes, antibodies against one O111 subtype can recognize and inhibit the adhesion to human epithelial cells of all categories of O111 E. coli (enteropathogenic E. coli [EPEC], enterohemorrhagic E. coli [EHEC], and enteroaggregative E. coli [EAEC]) strains regardless of the nature of their flagellar antigens, mechanisms of virulence, or O111 polysaccharide subtypes. These antibodies were also able to increase the clearance of different strains of O111 E. coli by macrophages. PCR analyses of the pathways involved in O111 LPS core biosynthesis showed that all EAEC strains have core type R2, whereas typical EPEC and EHEC have core type R3. In contrast, atypical EPEC strains have core types R2 and R3. In summary, the results presented herein indicate that the O111 polysaccharide and LPS core types R2 and R3 are antigen targets for panspecific immunotherapy against all categories of O111 E. coli.
机译:一个有前途的方法来开发一种疫苗反对O111 diarrheagenic菌株大肠杆菌表现出不同的机制毒力是核心或目标多糖链(O抗原)的脂多糖(LPS)。结构变化中找到这两个有限合伙人组件,使用它们作为抗原的目标接种疫苗,有必要制定疫苗能够诱导体液免疫应答能识别不同的变体在O111大肠杆菌菌株。表明,尽管差异寡糖重复单位组成O111ab和O111ac有限合伙人亚型之间,抗体O111亚型可以识别和抑制人类上皮细胞粘附细胞的所有类别的O111大肠杆菌(致肠病的大肠杆菌(EPEC),肠出血性大肠杆菌(EHEC),和enteroaggregative [EAEC])大肠杆菌菌株不管他们的鞭毛的本质抗原、毒性机制或O111多糖亚型。还能增加不同的间隙通过巨噬细胞O111大肠杆菌菌株。分析的途径参与O111有限合伙人核心生物合成显示,所有EAEC菌株核心类型R2,而典型的EPEC和肠出血性大肠杆菌感染核心类型R3。R2和R3菌株有核心类型。这里给出的结果表明R2和R3 O111多糖和有限合伙人核心类型抗原panspecific免疫疗法的目标吗对所有类别的O111大肠杆菌。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号